Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 5/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KLK8 | O60259 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.32 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19838193 | 0.98 | KLK1 (0.50) | KLK1KLK5CA1CA2CA12 | |
| SCHEMBL10268054 | 0.77 | KLK1 (0.45) | KLK1KLK5CA1CA2CA12 | |
| SCHEMBL12475273 | 0.76 | KLK1 (0.56) | KLK1KLK5KLK8F2PLAU | |
| SCHEMBL12475533 | 0.76 | KLK1 (0.56) | KLK1KLK5KLK8F2PLAU | |
| SCHEMBL1135209 | 0.76 | KLK1 (0.56) | KLK1KLK5KLK8F2PLAU | |
| SCHEMBL19647568 | 0.75 | KLK1 (0.44) | KLK1KLK5CA1CA2CA12 | |
| SCHEMBL8076597 | 0.75 | KLK1 (0.44) | KLK1KLK5CA1CA2CA12 | |
| SCHEMBL17837011 | 0.75 | KLK1 (0.44) | KLK1KLK5CA1CA2CA12 | |
| SCHEMBL17981792 | 0.75 | KLK1 (0.44) | KLK1KLK5CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL3446642 | 0.75 | KLK1 (0.58) | KLK1KLK5KLK8F2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735992-B | Method for crosslinking glycosaminoglycans | 国家科学研究中心 | 2023-12-05 | — | — | CN | disclosed |
| US-11807726-B2 | Method of crosslinking glycosaminoglycans | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-11-07 | — | — | US | disclosed |
| EP-4249492-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND ANTIBIOTIC COMPOSITION COMPRISING SAME | A&J Science Co.,Ltd. (KR) | 2023-09-27 | — | — | EP | disclosed |
| US-20220081519-A1 | METHOD OF CROSSLINKING GLYCOSAMINOGLYCANS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2022-03-17 | — | — | US | disclosed |
| US-11214655-B2 | Method of crosslinking glycosaminoglycans | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2022-01-04 | — | — | US | disclosed |
| CN-113735992-A | Method for cross-linking glycosaminoglycans | 高德美研究及发展公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3736296-B1 | METHOD OF CROSSLINKING GLYCOSAMINOGLYCANS | GALDERMA RES & DEV (FR) | 2021-09-15 | — | — | EP | disclosed |
| CN-110023341-B | Method for cross-linking glycosaminoglycans | 高德美研究及发展公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | ARS Pharmaceuticals, Inc. | 2021-05-27 | — | — | US | disclosed |
| EP-3736296-A1 | METHOD OF CROSSLINKING GLYCOSAMINOGLYCANS | Galderma Research & Development (FR) | 2020-11-11 | — | — | EP | disclosed |
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060196-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7816344-B2 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | KLK1 1578/4885KLK5 1864/4885CA1 4452/4885 |
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, FCGR3B, FCGR1A | KLK1 1889/4885KLK5 2237/4885CA1 3275/4885 |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | KLK1 2138/4885KLK5 2673/4885CA1 3768/4885 |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | KLK1 1578/4885KLK5 1864/4885CA1 4452/4885 |
| US-20220081519-A1 | METHOD OF CROSSLINKING GLYCOSAMINOGLYCANS | CD44, HPSE, CSGALNACT1 | KLK1 1271/4885KLK5 2545/4885CA1 1113/4885 |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | OXA1L, TLR1, OXER1 | KLK1 925/4885KLK5 2164/4885CA1 4867/4885 |
| US-11214655-B2 | Method of crosslinking glycosaminoglycans | CD44, HPSE, CSGALNACT1 | KLK1 1271/4885KLK5 2545/4885CA1 1113/4885 |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | KLK1 1578/4885KLK5 1864/4885CA1 4452/4885 |
| US-11807726-B2 | Method of crosslinking glycosaminoglycans | CD44, HPSE, CSGALNACT1 | KLK1 1271/4885KLK5 2545/4885CA1 1113/4885 |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | BRDT, BRI3BP, BTN3A1 | KLK1 3925/4885KLK5 4343/4885CA1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.